<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841293</url>
  </required_header>
  <id_info>
    <org_study_id>RC31-16-7940</org_study_id>
    <nct_id>NCT02841293</nct_id>
  </id_info>
  <brief_title>Cost-utility Evaluation of Two Strategies of Perineal Reconstruction After Abdominoperineal Resection for Anorectal Carcinoma</brief_title>
  <acronym>GRECCAR-9</acronym>
  <official_title>Cost-utility Evaluation of Two Strategies of Perineal Reconstruction After Abdominoperineal Resection for Anorectal Carcinoma: Perineal Filling With Biological Meshes vs. Primary Perineal Wound Closure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The originality of the GRECCAR project is to propose a holistic approach of the evaluation
      combining the paradigms of surgical efficacy, costs, quality of life and oncological
      adequacy, reflecting real life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abdominoperineal resection (APR) is required for the treatment of malignant tumours invading
      the anal external sphincter and / or pelvic floor muscles. APR is indicated for
      adenocarcinomas of the distal rectum and anal canal epidermoid carcinomas. Neoadjuvant
      radiochemotherapy is the standard treatment for both types of tumours before surgical
      resection. Yet, radiotherapy is the major factor of delayed or impaired healing of the
      perineum.

      Conventional APR in rectal cancer is associated with high rates of positive margins, tumor
      perforation and is independent risk factor for local recurrence. Therefore, a new approach,
      the extralevator APR (eAPR) that entails en bloc resection of the rectum, sphincter complex
      and levator muscles has emerged as a new standard of care. The current standard
      reconstruction technique is primary closure of perineum by absorbable sutures.

      Extralevator APR has enhanced perineal morbidity to rates of 40 to 60 % after neoadjuvant
      chemoradiation. Morbidity induces secondary surgical procedures, delayed hospital discharge,
      and prolonged perineal nursing up to 6 months. Besides human and financial requirements,
      perineal morbidity may also delay adjuvant chemotherapy. This resulted in a continuing debate
      on how to close the perineal defect after eAPR.

      Alternative techniques to primary closure of the perineum are immediate reconstruction by
      means of musculocutaneous flaps, and, recently, reconstruction using biologic meshes (dermal
      porcine acellular collagen matrix). Flaps are demanding techniques that require specific
      surgical skills; lengthen procedures and induce specific morbidity at the donor site.
      Moreover, flaps have their own rate of failure.

      Biological meshes are currently used as parietal reinforcement for abdominal wall hernias
      chest wall reconstruction or breast reconstruction after mastectomy. As expensive devices
      whose indications are expanding, biological meshes are subjected to cautious evaluation.
      Their use in pelvic reconstruction after APR has recently been described in retrospective
      studies. The technique is simple as opposed to musculocutaneous flaps and seems to offer the
      same morbidity of the perineal wound and a lower cost per patient than rectus abdominal flap.

      The originality of the GRECCAR project is to propose a holistic approach of the evaluation
      combining the paradigms of surgical efficacy, costs, quality of life and oncological
      adequacy, reflecting real life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cost Utility evaluation as assessed by quality-adjusted life year</measure>
    <time_frame>At 12 months</time_frame>
    <description>quality-adjusted life year will be estimated using the EQ-5D-3L questionnaire and corresponding value-set</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perineal wound healing according to the Southampton wound grading score</measure>
    <time_frame>At 12 months</time_frame>
    <description>Southampton wound grading score including :
Perineal wound infection
Breakdown of the perineal wound included any wound dehiscence, sinus or ulcer
Pelvic abscess
Perineal evisceration defined by exposure of the pelvic cavity through the perineal wound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity as assessed by visual analogic scale</measure>
    <time_frame>From date of randomization until the date of study participation end of patient, assessed up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity as assessed by visual analogic scale</measure>
    <time_frame>At 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity as assessed by visual analogic scale</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity as assessed by visual analogic scale</measure>
    <time_frame>At 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity as assessed by visual analogic scale</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Duration of nursing requirements with nursing time after discharge</measure>
    <time_frame>Through the completion of study 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Perineal hernia as assessed by magnetic resonance imaging</measure>
    <time_frame>Through the completion of study 12 months</time_frame>
    <description>Perineal hernia is defined as the protrusion of the abdominal content below the plane of the pelvic floor on magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Abdominoperineal Resection</condition>
  <arm_group>
    <arm_group_label>Group with biologic mesh</arm_group_label>
    <description>Data about Pelvic reconstruction using biologic mesh, cut to fit the patients perineal defect.
Clinical and medical parameters
Utility Cost evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with primary perineal closure</arm_group_label>
    <description>Data about subcutaneous tissue approximation. Then skin closure with absorbable interrupted sutures
Clinical and medical parameters
Utility Cost evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Utility Cost evaluation</intervention_name>
    <description>Medical consequences in terms of quality-adjusted life year and costs within the first year. quality-adjusted life year will be estimated using EQ-5D-3L scale</description>
    <arm_group_label>Group with biologic mesh</arm_group_label>
    <arm_group_label>Group with primary perineal closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical and medical parameters</intervention_name>
    <description>Cumulative dose and time duration of pain medication
Pain evaluation
Time to complete healing
Duration of nursing requirements after discharge
Perineal hernia symptomatic or not</description>
    <arm_group_label>Group with biologic mesh</arm_group_label>
    <arm_group_label>Group with primary perineal closure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with perineal reconstruction indication
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven rectal adenocarcinoma or anal canal epidermoid carcinoma

          -  Abdominoperineal resection indication after multidisciplinary team discussion. For
             rectal adenocarcinoma: circumferential MRI margin equal or less than 1 mm from closest
             tumoral structure and a striated muscular layer (levator ani or external anal
             sphincter). For epidermoid carcinoma: residual or recurrent tumour after
             chemoradiotherapy.

          -  Written informed consent

          -  Medical insurance

          -  Age â‰¥18

          -  Eastern Cooperative Oncology Group performance status 0-2

        Exclusion Criteria:

          -  Synchronous metastatic disease (UICC stage IV)

          -  T4 tumour needing extensive surgical resection followed by perineal reconstruction by
             a musculocutaneous flap.

          -  Previous pelvic radiotherapy for another disease than the rectal or anal cancer

          -  Crohn's disease

          -  Recent immunosuppressive drugs treatment

          -  Patient under juridical protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain KIRZIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain KIRZIN, MD</last_name>
    <phone>5 61 77 23 01</phone>
    <phone_ext>+33</phone_ext>
    <email>kirzin.s@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beaujon University Hospital</name>
      <address>
        <city>Beaujon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves Panis, MD</last_name>
      <email>yves.panis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Rullier, MD</last_name>
      <email>eric.rullier@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Luc Faucheron, MD</last_name>
      <email>jl.faucheron@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eddy Cotte, MD</last_name>
      <email>eddy.cotte@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paoli Camette Cancer Center of Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Lelong, MD</last_name>
      <email>lelongb@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valdaurellle cancer center of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phillipe Rouannet, MD</last_name>
      <email>eric.rullier@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy Cancer Center</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Marchal, MD</last_name>
      <phone>f.marchal@nancy.unicancer.fr</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume Meurette, MD</last_name>
      <email>guillaume.meurette@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Prudhomme, MD</last_name>
      <email>michel.prudhomme@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foch Cancer Center</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Bretagnol, MD</last_name>
      <email>frederic.bretagnol@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Intitute</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Dumont, MD</last_name>
      <email>frederic.dumont@igr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine University Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann PARC, MD</last_name>
      <email>yann.parc@sat.ap-hop-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Tuech, MD</last_name>
      <email>jean-jacques.tuech@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain Kirzin, MD</last_name>
      <phone>5 31 15 62 09</phone>
      <phone_ext>+33</phone_ext>
      <email>Kirzin.s@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anorectal cancer</keyword>
  <keyword>perineal morbidity</keyword>
  <keyword>cost-utility analysis</keyword>
  <keyword>biological meshes</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

